Abstract:[Abstract]Objective: To investigate the expression and clinical significance of long non-coding RNA (lncRNA) HMGA1P4 in hepatocellular carcinoma (HCC) tissues, and verify the regulatory mechanism of HMGA1P4 and miR4436a and its influence on the migration and invasion ability of hepatocellular carcinoma cell line. Methods: qRT-PCR was utilized to detect the expression of HMGA1P4 and miR4436a in hepatocellular carcinoma tissue microarrays; the correlation between HMGA1P4 expression in hepatocellular carcinoma tissues and the clinical pathological parameters or prognosis of patients was analyzed; the influence of HMGA1P4 and miR-4436a on the migration and invasion ability of the HepG2 cell line was verified by the transwell experiment; the regulatory relationship between HMGA1P4 and miR-4436a was verified by the dual luciferase report experiment.Results: HMGA1P4 was abnormally highly expressed in hepatocellular carcinoma tissues,whereas the expression of miR4436a was downregulated in hepatocellular carcinoma tissues; the abnormally high expression of HMGA1P4 was associated with lymph node metastasis, TNM staging, recurrence, serum γ-GGT levels, PD-L1, EGFR and CTLA-4 status, and among TNM Ⅰ-Ⅳ, TNM Ⅰ, TNM Ⅱ staging hepatocellular carcinoma patients, the overall survival rate and recurrence-free survival of hepatocellular carcinoma patients with high HMGA1P4 expression was significantly lower than low expression group. The high expression of HMGA1P4 was an independent risk factor for the poor prognosis of hepatocellular carcinoma patients.Transwell experiment revealed that downregulation of miR-4436a could reverse the inhibitory effect of HMGA1P4 silencing-mediated hepatocellular carcinoma cell migration and invasion,the dual luciferase report experiment showed that HMGA1P4 could regulate miR-4436a.Conclusion:The abnormally high expression of HMGA1P4 promotes the malignant biological behavior and poor prognosis of hepatocellular carcinoma. HMGA1P4 can promote the migration and invasion of hepatocellular carcinoma cells by regulating miR-4436a.
收稿日期: 2022-01-07
通讯作者:
石键(通讯作者),副主任技师,E-mail:shijianjyk@163.com
作者简介: 张云(1988—),女,主管技师,硕士
引用本文:
张云,石键. LncRNA HMGA1P4在肝细胞癌中的表达及其与miR-4436a调控关系的研究[J]. 江苏大学学报:医学版, 2022, 22(04): 338-344.
ZHANG Yun,SHI Jian. Expression of lncRNA HMGA1P4 in hepatocellular carcinoma and its correlation with the regulation of miR-4436a. Journal of Jiangsu University(Medicine Edition), 2022, 22(04): 338-344.
[1]Kulik L, ElSerag HB. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156(2): 477-491.
[2]Siegel RL, Miller KD. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[3]Xie H, Ma B, Gao Q, et al. Long noncoding RNA CRNDE in cancer prognosis: Review and metaanalysis[J]. Clinica Chimica Acta, 2018, 485(3): 262-271.
[4]Chi Y, Wang D, Wang J, et al. Long noncoding RNA in the pathogenesis of cancers[J]. Cells, 2019, 8(9): 232-236.
[5]Qiao XL, Zhong ZL, Dong Y, et al. LncRNA HMGA1P4 promotes cisplatinresistance in gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(17): 8830-8836.
[6]Zhang X, Zhang W, Jiang Y, et al. Identification of functional lncRNAs in gastric cancer by integrative analysis of GEO and TCGA data[J]. J Cell Biochem, 2019, 120(10): 17898-17911.
[7]Huang Z, Zhou JK, Peng Y, et al. The role of long noncoding RNAs in hepatocellular carcinoma[J]. Mol Cancer, 2020, 19(1): 77.
[8]周新童,任天宇,党胜春.长链非编码RNA AL139147.1在胃癌中的表达及对MKN45胃癌细胞生长的影响[J].江苏大学学报(医学版), 2021, 31(1): 51-55.
[9]Bakir B, Chiarella AM, Pitarresi JR, et al. EMT,MET, plasticity, and tumor metastasis[J]. Trends Cell Biol, 2020, 30(10): 764-776.
[10]Jiao X, Wang Y, Wang F, et al. Recurrence pattern and its predictors for advanced gastric cancer after total gastrectomy[J]. Medicine, 2020, 99(51): 23795.
[11]Wu Q, Jiang L, Li SC, et al. Small molecule inhibitors targeting the PD1/PDL1 signaling pathway[J]. Acta Pharmacologica Sinica, 2021, 42(1): 1-9.
[12]Dong Q, Du Y, Li H, et al. EGFR and cMET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma[J]. Cancer Res, 2019, 79(4): 819-829.
[13]Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)[J]. J Hematol Oncol, 2020, 13(1): 143.
[14]Kudo M. Scientific rationale for combined immunotherapy with PD1/PDL1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma[J]. Cancers, 2020, 12(5): 112-114.